DE69430823T2 - Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum - Google Patents

Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum

Info

Publication number
DE69430823T2
DE69430823T2 DE69430823T DE69430823T DE69430823T2 DE 69430823 T2 DE69430823 T2 DE 69430823T2 DE 69430823 T DE69430823 T DE 69430823T DE 69430823 T DE69430823 T DE 69430823T DE 69430823 T2 DE69430823 T2 DE 69430823T2
Authority
DE
Germany
Prior art keywords
antibiotic
bacteria
bpi
protein product
pleasureability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430823T
Other languages
English (en)
Other versions
DE69430823D1 (de
Inventor
Jonathan Cohen
Ada H C Kung
Lambert, Jr
Ii Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd USA
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Publication of DE69430823D1 publication Critical patent/DE69430823D1/de
Application granted granted Critical
Publication of DE69430823T2 publication Critical patent/DE69430823T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69430823T 1993-09-22 1994-09-22 Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum Expired - Fee Related DE69430823T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12565193A 1993-09-22 1993-09-22
US27340194A 1994-07-11 1994-07-11
PCT/US1994/011225 WO1995008344A1 (en) 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic

Publications (2)

Publication Number Publication Date
DE69430823D1 DE69430823D1 (de) 2002-07-18
DE69430823T2 true DE69430823T2 (de) 2003-02-20

Family

ID=26823793

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430823T Expired - Fee Related DE69430823T2 (de) 1993-09-22 1994-09-22 Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum

Country Status (13)

Country Link
US (2) US5523288A (de)
EP (1) EP0759774B1 (de)
JP (1) JPH09502987A (de)
AT (1) ATE218880T1 (de)
AU (1) AU695814B2 (de)
CA (1) CA2172245C (de)
DE (1) DE69430823T2 (de)
DK (1) DK0759774T3 (de)
ES (1) ES2178656T3 (de)
HK (1) HK1014155A1 (de)
NZ (1) NZ275205A (de)
PT (1) PT759774E (de)
WO (1) WO1995008344A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
PT759774E (pt) * 1993-09-22 2002-11-29 Xoma Technology Ltd Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
EP0839156A1 (de) * 1995-07-20 1998-05-06 Xoma Corporation Peptide gegen pilzbefall
AUPN771596A0 (en) 1996-01-25 1996-02-15 Mclean, Allan Joseph Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria
ATE198050T1 (de) 1996-05-10 2000-12-15 Xoma Technology Ltd Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
JP2000511190A (ja) * 1996-05-23 2000-08-29 ゾーマ コーポレイション 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US7067500B2 (en) * 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
JP2001523970A (ja) * 1997-05-02 2001-11-27 インテグレイテッド リサーチ テクノロジー，エルエルシー 感受性試験および抗菌治療のアジュバントとしてのベタイン
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
AU3642199A (en) * 1998-04-14 1999-11-01 Ribogene, Inc. Assays for inhibitors of bacterial translation initiation factor
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6790661B1 (en) * 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
US6696239B1 (en) * 2000-04-20 2004-02-24 Biolog, Inc. Comparative phenotype analysis for assessment of biological active compounds such as antimicrobials
WO2002055099A2 (en) 2000-12-01 2002-07-18 Xoma Technology Ltd Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
SI1341769T1 (sl) 2000-12-15 2008-02-29 Vertex Pharma Inhibitorji bakterijske giraze in njihove uporabe
US6835536B2 (en) * 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
CA2457885A1 (en) * 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
NZ541815A (en) * 2003-01-21 2008-07-31 Ecopia Biosciences Inc Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
US7300921B2 (en) * 2003-09-11 2007-11-27 Ecopia Biosciences, Inc. Polyene polyketides and methods of production
US20060106028A1 (en) * 2004-11-08 2006-05-18 Ecopia Biosciences, Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
EP1741440A1 (de) * 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
US8871929B2 (en) 2010-08-03 2014-10-28 Merck Sharp & Dohme Corp. Fused-imidazoyl compounds useful as antimicrobial agents
KR101897952B1 (ko) 2011-01-14 2018-09-12 스페로 트리넴, 인코포레이티드 피리미딘 자이라제 및 토포이소머라제 ｉｖ 억제제
WO2012112438A2 (en) * 2011-02-16 2012-08-23 The Penn State Research Foundation Anti-microbial agents and compositions and methods of production and use thereof
WO2012177707A1 (en) 2011-06-20 2012-12-27 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
AR093226A1 (es) 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
WO2014026143A1 (en) * 2012-08-09 2014-02-13 Pono Corporation Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof
WO2014160814A1 (en) * 2013-03-26 2014-10-02 Rutgers, The State University Of New Jersey Synthetic and enhanced bacterial killing involving bicyclomycin
CN109415411B (zh) * 2015-09-17 2022-06-28 首尔大学校产学协力团 表现出抗革兰氏阴性菌的抗微生物活性的断开或折叠的螺旋肽或肽类似物及其用途
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
US20210023101A1 (en) * 2017-07-19 2021-01-28 The University Of North Carolina At Chapel Hill Potentiation of antibiotic effect

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5028251A (de) * 1973-07-12 1975-03-22
JPS55134471A (en) * 1979-04-04 1980-10-20 Toshiba Corp Sales management system in small-scale computer constitution
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
JPS60128596A (ja) * 1983-12-15 1985-07-09 東芝テック株式会社 電子キヤツシユレジスタ
JPS619790A (ja) * 1984-06-25 1986-01-17 オムロン株式会社 電子式キヤツシユレジスタ
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
DE3856588T2 (de) * 1987-08-11 2006-09-07 New York University Biologisch-aktive Bakterizide/permeabilitätserhöhende Proteinbruchstücke
DE68929334T2 (de) * 1988-06-23 2005-08-18 Associates of Cape Cod, Inc., Falmouth Verfahren zumm Assay von Endotoxin-Konzentration
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
US5156665A (en) * 1991-01-03 1992-10-20 Rohm And Haas Company Antimicrobial compositions comprising iodopropargyl compounds and isothiazolones and methods of controlling microbes
AU2872792A (en) * 1991-09-26 1993-04-27 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
DK0642579T3 (da) * 1992-05-19 1999-10-18 Xoma Corp Forbedrede fremgangsmåder til fremstilling af endotoxin-bindende proteiner
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
DE69428521T2 (de) * 1993-02-02 2002-05-23 Xoma Technology Ltd Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
ATE165976T1 (de) * 1993-03-12 1998-05-15 Xoma Corp Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
NZ263057A (en) * 1993-03-12 2000-12-22 Xoma Corp Use of bactericidal permeability increasing proteins or derivative for treating chronic inflammatory diseases, neutralising heparin, inhibiting angiogenesis, tumour and epithelial cell proliferation
NZ263344A (en) * 1993-03-12 1997-08-22 Xoma Corp Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
PT759774E (pt) * 1993-09-22 2002-11-29 Xoma Technology Ltd Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico

Also Published As

Publication number Publication date
PT759774E (pt) 2002-11-29
US6140306A (en) 2000-10-31
CA2172245C (en) 2003-04-08
US5523288A (en) 1996-06-04
CA2172245A1 (en) 1995-03-30
AU8074094A (en) 1995-04-10
NZ275205A (en) 1998-03-25
HK1014155A1 (en) 1999-09-24
EP0759774A1 (de) 1997-03-05
WO1995008344A1 (en) 1995-03-30
DK0759774T3 (da) 2002-10-07
DE69430823D1 (de) 2002-07-18
AU695814B2 (en) 1998-08-20
ES2178656T3 (es) 2003-01-01
EP0759774B1 (de) 2002-06-12
JPH09502987A (ja) 1997-03-25
ATE218880T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
DE69430823T2 (de) Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
DE69527195D1 (de) Anti gram positive bakterielle verfahren und mittel
Hitomi et al. Control of a methicillin-resistant Staphylococcus aureus outbreak in a neonatal intensive care unit by unselective use of nasal mupirocin ointment
ATE329031T1 (de) Therapeutische zusammensetzungen zur behandlung von lawsonia intracellularis infektionen
ATE109624T1 (de) Bakteriocine enthaltende zusammensetzungen zur verwendung als verbesserte breitspektrum- bakterizide und verfahren zur verhütung und behandlung von mikrobiellen infektionen.
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
RU93004457A (ru) 1-карба-(1-детиа)-цефемы и промежуточные продукты для их получения
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
EP0579488B1 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
ATE182470T1 (de) Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung
Gadberry et al. Pasteurella pneumotropica isolated from bone and joint infections
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
Schrank Jr et al. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia
ATE201995T1 (de) Verfahren zur prävention und behandlung der rindermastitis
HUP0401586A2 (hu) Baktériumellenes szer
Weidner et al. Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin
Mastsui et al. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer
FR2696179B1 (fr) Derives de thioalkylthiocarbacephalosporine, procede pour leurs preparations et formulation pharmaceutique les contenant pour le traitement ou la prophylaxie des infections bacteriennes.
DE60228324D1 (de) Verfahren zur behandlung von bakteriellen infektionen mit gemifloxacin oder einem seiner salze und einem antibakteriellen carbapenem-mittel
Bustamante Initial empiric therapy for fever in neutropenia
Mandell Management of the febrile neutropenic patient.
ZA947394B (en) Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee